Updated from 1:43 p.m. EDT

Shares of

Gen-Probe

(GPRO) - Get Report

were among the best-performing health and pharmaceutical stocks Friday, rising 14.7% after the company posted strong third-quarter earnings.

The diagnostics company earned 22 cents a share on sales of $63.5 million. Analysts polled by Thomson First Call were expecting earnings of 19 cents a share on sales of $60.5 million. For the full year, Gen-Probe forecast earnings of $1.02 to $1.03 a share on sales of $262 million to $264 million. Analysts are looking for earnings of $1.02 a share on sales of $260.3 million. Shares traded up $4.86 to $37.86.

Angiotech Pharmaceuticals

( ANPI) rose 5.7% after the company posted third-quarter earnings and sales above expectations. The pharmaceutical company earned 31 cents a share on sales of $44.3 million. Analysts were expecting earnings of 25 cents a share on sales of $42.3 million. Third-quarter sales included $40.4 million in royalties received from

Boston Scientific

(BSX) - Get Report

as part of a licensing agreement related to the Taxus drug-eluting stent. Shares traded up $1.09 to $20.37.

Shares of

ProxyMed

(PILL) - Get Report

fell 8.9% after the company posted mixed third-quarter results and warned that it would post a fourth-quarter loss. During the third quarter the medical cost containment services company posted a loss of 8 cents a share on sales of $22.5 million. Analysts were expecting a loss of 10 cents a share on sales of $22.7 million. Looking ahead, ProxyMed forecast a fourth-quarter loss of 6 cents to 10 cents a share on sales of $22 million to $23 million. Analysts had been expecting a profit of 6 cents a share on sales of $23.3 million. Shares traded down 84 cents to $8.65.

Rigel Pharmaceuticals

(RIGL) - Get Report

rose modestly after the company posted third-quarter financial results. For the third quarter, the company posted a loss of 88 cents a share on sales of $659,000. Analysts were expecting a loss of 71 cents a share on sales of $1.54 million. A year ago Rigel posted a loss of 78 cents a share on sales of $2.1 million. Shares traded up 13 cents to $26.

AMN Healthcare

(AHS)

rose 21.6% after the company posted in-line third-quarter financial results and said that fourth-quarter sales would be above expectations. The health care staffing company earned 13 cents a share during the third quarter on sales of $156.1 million. Looking ahead, the company forecast fourth-quarter earnings of 13 cents to 15 cents a share on sales of $155 million to $160 million. Analysts had been expecting earnings of 14 cents a share on sales of $154.2 million. Shares traded up $2.42 to $13.63.

Other health care volume movers included

Merck

(MRK) - Get Report

, down 81 cents to $26.21;

Pfizer

(PFE) - Get Report

, down 27 cents to $28.79;

Amgen

(AMGN) - Get Report

, up $1.66 to $60.66;

Teva Pharmaceutical Industries

(TEVA) - Get Report

, up $1.09 to $25.01; and

StemCells

(STEM)

, up 17 cents to $3.07.